memantine has been researched along with Pyrexia in 3 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Three phase 2 trials were conducted to assess the efficacy and long-term safety of weight-based memantine extended release (ER) treatment in children with autism spectrum disorder." | 9.30 | Efficacy and safety of memantine in children with autism spectrum disorder: Results from three phase 2 multicenter studies. ( Ali, S; Aman, MG; Andersen, KA; Graham, SM; Hardan, AY; Hendren, RL; Jia, XD; Lateiner, JE; Luchini, R; Mallick, M; Melmed, RD; Palmer, RH; Rahman, R; Robb, A, 2019) |
| "Pretreatment with risperidone (0." | 5.32 | Memantine, an NMDA antagonist, prevents the development of hyperthermia in an animal model for serotonin syndrome. ( Kato, S; Nisijima, K; Shioda, K; Takano, K; Yoshino, T, 2004) |
| "Three phase 2 trials were conducted to assess the efficacy and long-term safety of weight-based memantine extended release (ER) treatment in children with autism spectrum disorder." | 5.30 | Efficacy and safety of memantine in children with autism spectrum disorder: Results from three phase 2 multicenter studies. ( Ali, S; Aman, MG; Andersen, KA; Graham, SM; Hardan, AY; Hendren, RL; Jia, XD; Lateiner, JE; Luchini, R; Mallick, M; Melmed, RD; Palmer, RH; Rahman, R; Robb, A, 2019) |
| "Pretreatment with risperidone (0." | 1.32 | Memantine, an NMDA antagonist, prevents the development of hyperthermia in an animal model for serotonin syndrome. ( Kato, S; Nisijima, K; Shioda, K; Takano, K; Yoshino, T, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hardan, AY | 1 |
| Hendren, RL | 1 |
| Aman, MG | 1 |
| Robb, A | 1 |
| Melmed, RD | 1 |
| Andersen, KA | 1 |
| Luchini, R | 1 |
| Rahman, R | 1 |
| Ali, S | 1 |
| Jia, XD | 1 |
| Mallick, M | 1 |
| Lateiner, JE | 1 |
| Palmer, RH | 1 |
| Graham, SM | 1 |
| Nisijima, K | 2 |
| Kuboshima, K | 1 |
| Shioda, K | 2 |
| Yoshino, T | 2 |
| Iwamura, T | 1 |
| Kato, S | 2 |
| Takano, K | 1 |
1 trial available for memantine and Pyrexia
| Article | Year |
|---|---|
Efficacy and safety of memantine in children with autism spectrum disorder: Results from three phase 2 multicenter studies.
Topics: Autism Spectrum Disorder; Child; Delayed-Action Preparations; Double-Blind Method; Early Termination | 2019 |
2 other studies available for memantine and Pyrexia
| Article | Year |
|---|---|
Memantine attenuates 3,4-methylenedioxymethamphetamine-induced hyperthermia in rats.
Topics: Animals; Brain Chemistry; Chromatography, High Pressure Liquid; Dopamine; Dopamine Agents; Fever; Ha | 2012 |
Memantine, an NMDA antagonist, prevents the development of hyperthermia in an animal model for serotonin syndrome.
Topics: 5-Hydroxytryptophan; Animals; Body Temperature; Clorgyline; Disease Models, Animal; Dizocilpine Male | 2004 |